According to The Insight Partners’ research, the global colorectal cancer marketis anticipated to gather US$ 22,953.8 million by 2027 from US$ 16,339.9 million in 2018, growing at 4.0% CAGR from 2019 to 2027. Growing prevalence of colorectal cancer, launch of new products, and benefits offered by generic drugs are the vital factors contributing to market expansion.
The market for colorectal cancer drugs is driven by frequent diagnostic tests and drug launches. Most of the major market players are involved in the manufacturing wide range of drugs and diagnostic tests that help in reducing the burden of colorectal cancer. For instance, in June 2019, Pfizer, Inc. launched ZIRABEV, a biosimilar to Avastin that helps in the treatment of five cancers, including colorectal cancer.
Get Sample Copy of Report PDF: https://www.theinsightpartners.com/sample/TIPRE00006881/
Colorectal cancer is one of the commonly found and lethal cancers which is developed in an individual with the combined influence of genetic and environmental factors. Additionally, according to the World Health Organization (WHO), colorectal cancer was the third most prevalent form of cancers, with approximately 1.80 million cases around the world in 2018, excluding skin cancer. The rates of colorectal cancer mortality and incidence vary across the globe as per the reports by WHO’s cancer database GLOBOCAN. The GLOBOCAN reports approximately 861,000 deaths in 2018 due to colorectal cancer.
Moreover, in September 2019, Lupin, an Indian pharmaceutical company, partnered with German-based Boehringer Ingelheim pharmaceutical company for the development of cancer drugs. The companies came together to develop and commercialize a drug based on the MEK inhibitor. This molecule is likely to target specific cancer cells and treat patients suffering from stomach and skin cancer. These drug launches will drive market expansion over the forecast timeframe. On the other hand, pricing pressure on drug manufacturers will likely hinder market proliferation over the analysis timeframe.
Based on modality, the global colorectal cancer market is divided into diagnosis, therapy, and imaging types. Among these, the diagnosis-type segment held 38.2% of the market share in 2018. The segment was assessed at US$ 6,247.0 million in 2018 and is anticipated to reach US$ 9,219.3 million by 2027, growing at 4.5% CAGR during the forecast period.
From the regional frame of reference, North America held a significant share in the global colorectal cancer market in 2018. The region was evaluated at US$ 7,452.6 million in 2018 and is estimated to accrue US$ 10,655.1 million by 2027, growing at 4.2% CAGR between 2019 and 2027. Meanwhile, APAC is predicted to record a stellar growth rate of 4.5% CAGR over the analysis timeframe and gather US$ 4900.6 million by 2027.
As per end user spectrum, the market is split into hospitals and diagnostic & research laboratories. Among these, the hospitals segment captured 58.6% of the market share in 2018. The segment was evaluated at US$ 9,576.3 million in 2018 and is estimated to expand at a CAGR of 4.3% during 2019–2027 to amass US$ 13,859.0 million by 2027.
From the regional perspective, Asia Pacific dominated the market by capturing 29.7% in 2020, expected to hold a share of 35.1% by 2028. The region’s market value was US$ 1,481.48 million in 2020 and is anticipated to reach US$ 2,551.26 million by 2028 with a CAGR to record a growth rate of 7.3% over the forecast period.
Key companies enlisted in the global colorectal cancer market report are Epigenomics AG; Novigenix SA; Clinical Genomics Technologies Pty Ltd; EDP Biotech Corporation; VolitionRx Limited; Abbott Laboratories; Amgen Inc.; F. Hoffmann-La Roche AG; Bruker Corporation; Quest Diagnostics Inc.; Natera, Inc.; and Guardant Health, Inc.
- In August 2019, Natera, Inc. announced that Palmetto MolDX program has proposed a local coverage determination for using the company’s Signatera molecular residual disease for the patients living with certain forms of colorectal cancer (CRC).
- In March 2019, Guardant Health, Inc. announced it has signed an agreement with Bellwether Bio, Inc., to acquire its pioneering research into the epigenomic content of cell free DNA.
- In November 2017, Quest Diagnostics and Clinical Genomics together announced FDA clearance of InSure ONE, which is a convenient at-home collection, fecal immunochemical test which is used to detect blood in stool that may improve compliance for screening programs.
Browse More Information: https://www.theinsightpartners.com/reports/colorectal-cancer-market
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]